Risk Stratification for Bladder Tumor Recurrence, Stage and Grade by Urinary Nuclear Matrix Protein 22 and Cytology

European Urology

Volumn 45, Issue 3, 2004, Pages 304-313

  Shariat, Shahrokh F ^a   Casella, Roberto ^b   Wians Jr , Frank H ^c   Ashfaq, Raheela ^c   Balko, Jody ^c   Sulser, Tullio ^b   Gasser, Thomas C ^b   Sagalowsky, Arthur I ^a   Irani, Jacques ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d NONE

Author keywords

Bladder cancer; Diagnosis; Nuclear matrix protein 22; Stage; Urine

Indexed keywords

NUCLEAR MATRIX PROTEIN; NUCLEAR MATRIX PROTEIN 22; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BLADDER CANCER; BLADDER CARCINOMA; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MICTURITION; PREDICTION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; QUANTITATIVE ANALYSIS; RECURRENCE RISK; RISK ASSESSMENT; TRANSITIONAL CELL CARCINOMA; URINALYSIS; URINE CYTOLOGY;

EID: 1242315460     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2003.10.020     Document Type: Article

References (20)

1. J.N. Gordon W.P. Shu R.N. Schlussel M.J. Droller B.C.S. Liu Altered extracellular matrices influence cellular processes and nuclear matrix organisations of overlying human bladder urothelial cells Cancer Res. 53 1993 4971 4977
2. R. Berezney D.S. Coffey Identification of a nuclear protein matrix Biochem. Biophys. Res. Commun. 60 1974 1410 1417
3. D.A. Compton D.W. Cleveland NuMA is required for the proper completion of mitosis J. Cell Biol. 120 1993 947 957
4. Y. Lotan C.G. Roehrborn Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses Urology 61 2003 109 118
5. M.S. Soloway J.V. Briggman G.A. Carpinito G.W. Chodak P.A. Church D.L. Lamm Use of a new tumor marker, urinary NMP22 in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment J. Urol. 156 1996 363 367
6. H.G. Wiener C. Mian A. Haitel A. Pycha G. Schatzl M. Marberger Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J. Urol. 159 1998 1876 1880
7. S. Ramakumar J. Bhuiyan J.A. Besse S.G. Roberts P.C. Wollan M.L. Blute Comparison of screening methods in the detection of bladder cancer J. Urol. 161 1999 388 394
8. C.D. Sharma S C.D. Gippe L. Pandrangi D. Nelson A. Agarwal Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat J. Urol. 162 1999 53 57
9. J. Landman Y. Chang E. Kavaler M.J. Droller B.C. Liu Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer Urology 52 1998 398 402
10. N. Miyanaga H. Akaza T. Tsukamoto S. Ishikawa R. Noguchi M. Ohtani Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria Int. J. Urol. 6 1999 173 177
11. J.H. Hughes R.L. Katz J. Rodriguez-Villanueva L. Kidd C. Dinney H.B. Grossman Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder Diagn. Cytopathol. 20 1999 285 290
12. C. Zippe L. Pandrangi J.M. Potts E. Kursh A. Novick A. Agarwal NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer Anticancer Res. 19 1999 2621 2623
13. A. Del Nero N. Esposito A. Curro D. Biasoni E. Montanari B. Mangiarotti Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test Eur. Urol. 35 1999 93 97
14. V. Serretta D. Lo Presti P. Vasile E. Gange E. Esposito I. Menozzi Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients Urology. 52 1998 793 796
15. J.A. Witjes H.G. van der Poel M.R. van Balken F.M. Debruyne J.A. Schalken Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer Eur. Urol. 33 1998 387 391
16. M. Greiner Two-graph receiver operating characteristic (TG-ROC): update version supports optimisation of cut-off values that minimise overall misclassification costs J. Immunol. Methods 191 1996 93 94
17. M. Greiner D. Sohr P. Gobel A modified ROC analysis for the selection of cut-off values and the definition of intermediate results of serodiagnostic tests J. Immunol. Methods 185 1995 123 132
18. E.R. DeLong D.M. DeLong D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837 845
19. Y. Lotan C.G. Roehrborn Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach J. Urol. 167 2002 75 79
20. J.L.J. Vriesema M.H. Poucki L.A.L.M. Kiemeney J.A. Witjes Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: a utility analysis Urology 56 2000 793 797